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Purpose: The triple-H therapy is widely used for cerebral vasospasm (CV) prevention and
treatment in patients after subarachnoid haemorrhage (SAH). However, this practice is
based on low level evidence. Aim of this study was to evaluate errors in ﬂuid administration,
ﬂuid balance monitoring and bedside charts completeness during a trial of triple-H therapy.
Materials and methods: An audit of the SAH patient charts was performed. A total of 508 ﬂuid
measurements were performed in 41 patients (6 with delayed cerebral ischaemia; DCI)
during 14 days of observation.
Results: Underestimating for intravenous drugs was the most frequent error (80.6%; 112),
resulting in a false positive ﬂuid balance in 2.4% of estimations. In 38.6% of the negative ﬂuid
balance cases, the physicians did not order additional ﬂuids for the next 24 h. In spite of that,
the ﬂuid intake was signiﬁcantly increased after DCI diagnosis. The mean and median intake
values were 3.5 and 3.8 l/24 h respectively, although 40% of the ﬂuid balances were negative.
The positive to negative ﬂuid balance ratio was decreasing in the course of the 14 day
observation.
Conclusions: This study revealed inconsistencies in the ﬂuid orders as well as mistakes in the
ﬂuid monitoring, which illustrates the difﬁculties of ﬂuid therapy and reinforces the need for
strong evidence-based guidelines for hypervolemic therapy in SAH.
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1.1. Purpose
The purpose of this study was to measure the physicians'
adherence to ﬂuid intake recommendations and the accuracy
of ﬂuid status monitoring by the nurses at the NICU
(Neurosurgical Intensive Care Unit) and the NHDU (Neurosur-
gical High-Dependency Unit). More speciﬁcally, we aimed to
ﬁnd whether more errors occurred at a speciﬁc ward (NICU vs.
NHDU) or during a stage of treatment (before vs. after
occurrence of DCI; Delayed Cerebral Ischaemia) and whether
they were attributed to the neurointensivists or the nurses.
The following baseline hypotheses were presumed: better
ﬂuid monitoring in the NICU than NHDU and higher adherence
to the recommendations by nurses than physicians.
1.2. Background
The most common cause of subarachnoid haemorrhage (SAH)
is a ruptured cerebral aneurysm, which is associated with high
mortality and morbidity rates [1]. If a patient survives the SAH,
early neurosurgical or endovascular aneurysm-securing pro-
cedures are preferred as rebleeding occurs in up to 17% of cases
within the ﬁrst 72 h [2]. Thereafter, an intensive care nursing
team deals with both the general and the SAH-speciﬁc critical
care principles including the prevention, diagnosis and treat-
ment of cerebral vasospasm (CV). The clinical signs of
neurological deterioration are associated with delayed cerebral
ischaemia (DCI), which may be the consequence of CV [3].
Hypovolemia is one of the factors responsible for lowering
brain perfusion, correlated with DCI and CV development after
SAH [4]. Healthy humans need two litres of water per day [5], but
after SAH the daily ﬂuid intake should increase to 3.0–3.5 l [4].
Hypertensive hypervolemic hemodilution (triple-H thera-
py) is a simple treatment concept, which is widely used for the
prevention and treatment of CV after SAH and thus to reduce
DCI rate [6–8]. Its aim is to increase the cerebral blood
perfusion pressure, which was shown in some preliminary
studies [9–11]. Authors supported the use of triple-H therapy in
CV treatment and emphasised the beneﬁcial role of prophy-
lactic hypervolemia and hypertension in the clinical outcome
[12,13]. There is a consensus among the specialists regarding
the triple-H therapy in patients with symptomatic vasospasm
[8]. However, as of yet there are no meta-analyses, or large,
prospective and randomised trials proving the effectiveness
and safety of the triple-H therapy or its separate components
[9]. Only three small and inconclusive RCTs were conducted so
far [14–16]. Furthermore, there are no published guidelines for
the diagnosis and treatment of CV [17]. Moreover, hypervo-
lemia and hypertension are related to the complications,
including cardiopulmonary failure, renal dysfunction, pulmo-
nary oedema, exacerbation of cerebral oedema or rupture of
the partially-secured aneurysm [4,14,18–20]. If administered to
inappropriately selected patients, the hypervolemic therapy
may lead to a prolonged stay at an intensive care and poor
neurological outcomes [20]. For this reason, the unproven
beneﬁts of the triple-H therapy should outweigh the potential
complications. Furthermore, the current recommendations forhypervolemic therapy in SAH are based on low-level evidence,
are regarded as difﬁcult to follow in case of conscious patients
with oral ﬂuid intake and need further study [4].
2. Materials and methods
2.1. Inclusion criteria
We performed a prospective clinical observation of triple-H
therapy in patients operated due to a ruptured cerebral
aneurysm derived from anterior circulation in September
2009–March 2011 at one of the regional neuroscience centres in
Europe (catchment area of approximately 2 million inhabi-
tants, with supraregional referrals of patients with SAH). All
grades of radiological appearance of haemorrhage (Fisher
scale 1–4) diagnosed by computer tomography (CT) imaging
were accepted. The study was restricted to neurosurgical
clipping followed by ventriculostomy, therefore patients after
endovascular treatment were excluded. The time from initial
SAH symptoms to neurosurgical clipping of ruptured aneu-
rysm was ≤48 h. Neurological status was evaluated on
admission using the Hunt-Hess scale, Glasgow Coma Scale
(GCS) and World Neurosurgical Federation Scale (WFNS). Poor
clinical condition on admission (Hunt-Hess grade 4 or 5 and
WFNS grade IV or V), endovascular aneurysm securing, surgery
>48 h from admission, large intracerebral haematoma evacua-
tion or postoperative deep sedation comprised the exclusion
criteria (Fig. 1). NICU postoperative care always preceded further
NHDU stay. Ambulating patients were routinely transferred
from NICU to NHDU after two days post-surgery. The observa-
tion period of ﬂuid balance started from the day of admission
to NICU and lasted for the following 14 days after SAH. Patients
remained under the care of neurointensivists (neurosurgeons
or neurosurgical anaesthesiologists).
2.2. Study protocol
After a literature review on the triple-H therapy, the
neurointensivists developed the departmental recommen-
dations for standard ﬂuid management after SAH (Tables 1a
and 1b). All the medical personnel were reminded of the
above departmental recommendations just before the start
of the study. Neurointensivists ordered the ﬂuids. Total
intravenous and oral ﬂuid intake, ﬂuid output and balance
were manually noted, monitored and collected at the bedside
by nurses. At least two nurses working in 12-hour shifts
completed the daily ﬂuid measurements. Electrolyte abnor-
malities and haemoglobin were monitored routinely every
twelve hours. Signiﬁcant anaemia requiring erythrocyte
mass transfusion was deﬁned as haemoglobin level <9 g/dL.
The neurological condition of patients was veriﬁed every
6 h (2 h) by a neurosurgeon using the GCS and National
Institutes of Health Stroke Scale (NIHSS). The diagnosis of
neurological deterioration was established by a decrease of the
GCS score by 1 or the NIHSS score by 2 points. The complete
diagnosis of DCI (as a clinical sign of CV) was established after
the exclusion of other causes of deterioration. Septicaemia,
anaemia, electrolyte abnormalities, hydrocephalus, cerebral
oedema or seizures were veriﬁed by physical, laboratory,
Fig. 1 – Flow chart showing the patient selection process.
SAH – subarachnoid haemorrhage; WFNS – World
Neurosurgical Federation Scale; ICH – intracerebral
haematoma; mL – millilitres.
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of CV in CT angiography or digital subtraction angiography
was obligatory. The management for DCI patients included all
components of triple-H therapy. When a patient completed
the observation period, investigators thoroughly recalculated
all ﬂuids (intake, output and balance) and compared them with
the total values from bedside charts. The protocol of this study
was accepted by the University's Ethics Committee.
Descriptive statistical methods were used to characterise
the patient group. Selection of adequate statistical testing was
based on the normal distribution of continuous variables,
which were conﬁrmed by the Kolmogorov–Smirnov test. The
Student's t-test or the non-parametric Mann–Whitney U-test
were applied for comparisons of continuous variables. The
analysis of recalculated sums of ﬂuid intake, output and
balance were performed using the Student's t-test or Pearson's
correlation. Statistica v.10.0 (StatSoft, Inc.) software with
signiﬁcance ( p-value) set at <0.05 was used for all calculations.
3. Results
3.1. Baseline patient characteristics
The study consisted of 41 patients: 27 (65.8%) females and
14 males (34.2%), aged 18–75 years old (mean age = 50.7 years(SD  12.9)), with 4 patients (9.8%) >65 years old. 51.2% (n = 21)
of the patients were treated for arterial hypertension, whereas
46.5% (n = 19) had a Body Mass Index (BMI) >25. For the
majority of patients the only pre-admission clinical signs of
aneurysm rupture were severe headache, vomiting and nuchal
rigidity, whereas 12 (29.3%) experienced a transient loss of
consciousness and 2 patients (4.9%) developed seizures. Other
SAH-speciﬁc symptoms were noted in 13 cases (31.7%).
Aneurysm size, location, patient's clinical condition (Hunt-
Hess, GCS, WFNS scales) as well as haemorrhage appearance
in CT imaging (Fisher scale) was evaluated for all cases on
admission (Table 2). Four patients died before end of the study.
3.2. Vasospasm occurrence
Transient or persistent neurological deterioration during
hospitalisation was noted in 10 patients (24.4%). In 2 cases
DCI was excluded as isolated cerebral oedema without
ischaemia, based on CT imaging in absence of angiographic
CV. One signiﬁcant early neurosurgical complication occurred:
vast ischaemia derived from the anterior cerebral artery and
rebleeding from an unsecured aneurysm. A total of 3 patients
died: 2 of brain oedema and 1 of the aforementioned early
neurosurgical complication. In one case, signiﬁcant anaemia
resulted in a transient 2 point decrease in the GCS score, with
recovery after erythrocyte mass transfusion. There was no
observed neurological deterioration due to hydrocephalus,
septicaemia, electrolyte abnormalities or seizures.
Out of 10 patients with neurological deterioration, 6 were
affected by DCI. In 3 cases, cerebral subtraction angiography
conﬁrmed DCI resulting from CV. Median time from the initial
SAH to DCI occurrence was 4 days (2–11; mean = 5.3; SD  3.5).
Transient neurological deterioration due to DCI was noted in 4
patients. One patient with DCI died (9 days post-op). DCI
resulted in permanent neurological deﬁcit on discharge in 2
other cases. No adverse events related to hypervolemia
therapy were noted.
3.3. Fluid measurement considerations
The patients' ﬂuid volume on the day of the surgery varied
from 3534 to 10,020 mL due to different intraoperative volume
intake. Hence, the analysis of volume status began on the ﬁrst
postoperative day and lasted for the following thirteen days
(Fig. 2). Out of the 508 ﬂuid level charts, 322 were complete
(63.4%) in the whole group, 49 were complete in the DCI group
(49 of 74; 66.2%) and 273 from patients without or before DCI
(273 of 434; 62.9%). There were no signiﬁcant differences in the
chart completeness of patients with and without DCI (p = 0.60).
However, the ﬂuid charts in the NICU were signiﬁcantly
(p < 0.01) more often complete (80.2%; 89 of 111) than in the
NHDU (58.7%; 233 of 397). The proportion of complete to
incomplete ﬂuid balance records was decreasing parallel to
the presence of central venous line (CVL) over time. In the
whole observation period, the percentage of patients with
complete ﬂuid balance measurement (61.6%) was higher than
the percentage of cases with (CVL) (63.4%; p < 0.01) (Fig. 3).
The audit of ﬂuid intake and balance charts revealed
numerous errors. Fluid intake miscalculations (139 of 508;
27.4%) resulted in incorrect net ﬂuid balance. The most
Table 1a – Intraoperative and departmental recommendations for fluid therapy after SAH.
Intraoperative management
Recommendation Induction Pre-clipping Post-clipping period
Anaesthetics Etomidate iv
#ICP; #CBF, RR unchanged
Propofol iv (target controlled infusion)
#ICP, #CBF, #RR
Arterial blood pressure Norepinephrine (if needed, especially during
induction with Etomidate)
SBP 120–140 mmHg is maintained until
clipping.
Norepinephrine (usually needed)
SBP 140–160 mmHg is maintained
Crystalloid solution Crystalloids to maintain normovolemia (SAH
induces a hypovolemic state; a patient
requires 3 l)
Hypervolemia (CVP 10) maintained with crystalloids
+0.5 l of HES
Colloid solution None 0.5 l dextran 40,000
Overall ﬂuid balance Neuroanaesthesiologists ordered volumes of crystalloids and were responsible for ﬂuid balance maintenance. Total ﬂuid
intake depended on time of surgery, clinical status at admission and blood loss. The study protocol did not inﬂuence ﬂuid
balance during the surgery.
Postoperative management
Recommendation Volume [daily] Period
Colloid solution 0.25 l of dextran 40,000 Five days following surgery
Crystalloid solution 0.5 l of HES Five days following surgery
Intravenous intake >1.5 l of crystalloids (5% dextrose
and/or multi-electrolyte solution)
Duration of the observation period (13 days)
Intake volumes >3 l Duration of the observation period (13 days)
Additional intakes
(if patient's temperature >37.0 8C)
0.5 l of crystalloids for every 1 8C Till patient's temperature <37.0 8C
Overall ﬂuid balance
and arterial blood pressure
Neurointensivists ordered volumes of crystalloids and nurses were responsible for ﬂuid balance
maintenance. There were not developed any strict recommendations for RR maintenance; neurointen-
sivists ordered norepinephrine if MAP < 90 mmHg.
Abbreviations: ICP – intracranial pressure; CBF – cerebral blood ﬂow; RR – blood pressure; SBP – systolic blood pressure; CVP – central venous
pressure; MAP – mean arterial pressure; HES – hydroxyethyl starch.
Table 1b – Departmental recommendations for management for DCI patients.
Recommendation Medication Target
Blood pressure Norepinephrine SBP > 140 mmHg
Volume of intake 0.25 l dextran 40,000 and 0.5 l HES >5 days
Total volume of ﬂuid intake Exceeding 3.5 l
Neurointensivists ordered volumes of crystalloids and nurses were responsible for ﬂuid balance maintenance.
Abbreviations: SBP – systolic blood pressure; HES – hydroxyethyl starch.
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mation of intake (80.6%; 112 of 139), most often due to omitting
the volume of the intravenous drugs (66.9%; 93 of 139). The
retrospective recalculations of ﬂuid intake resulted in a change
of ﬂuid balance from net negative to net positive in 12 cases (12
of 508; 2.4%). Many abnormalities in positive balance mainte-
nance were noticed. As per the departmental recommenda-
tions, additional ﬂuids should be ordered for the following day
(excluding 25 measurements upon discharge or patients'
death), yet 101 occurrences of negative ﬂuid balance there
were noted (101 of 483; 20.9%). Furthermore, in 1/3 of these
cases (39 of 101; 38.6%) the same or even smaller amounts of
ﬂuids were administered. As many as 41.2% (7 of 17) of patients
diagnosed with DCI and 38.1% (32 of 84) of patients without DCI
had negative ﬂuid balance occurrences in which additional
amounts of ﬂuid were not dispensed. There were no signiﬁcant
differences between patients with and without DCI in terms of
additional ﬂuid supplementation after the occurrence of a
negative balance (p = 0.06).3.4. Fluid balance analysis
Mean and median ﬂuid intake values in the DCI and non-DCI
groups exceeded 3.5 l per 24 h. A quarter of the patients
received <3 l of ﬂuids before DCI was diagnosed. The
comparison of intake records revealed that DCI occurrence
prompted physicians to dispense additional ﬂuids. The
difference in mean ﬂuid intake values before and after DCI
diagnosis was only 283 mL (p = 0.02), resulting in an insigniﬁ-
cant 75 mL increase in the mean ﬂuid balance. There were no
differences in the mean ﬂuid output, mean ﬂuid balance
values, nor in the positive ﬂuid balance ratios between DCI and
non-DCI patients. Therefore, the desired hypervolemic effect
of the triple-H therapy was not achieved (Fig. 4).
Wide ranges of ﬂuid balance values and low percentage of
positive ﬂuid balance were noted in both DCI and non-DCI
groups. The proportion of positive to negative ﬂuid balance
occurrences in the whole group were signiﬁcantly decreasing
over time (r = 0.22; p < 0.01). It started from 84.6% on the day
Table 2 – Baseline patient characteristics.
n; %
Aneurysm size >15 mm 34; 83.3%
Location
ACA 4; 9.8%
MCA 8; 19.5%
ICA 12; 29.3%
ACoA 16; 39.0%
Frontopolar artery 1; 2.4%
WFNS
Grade I (GCS 15) 21; 51.2%
Grade II (GCS 13–14) 16; 39.0%
Grade III (GCS 13–14) 4; 9.8%
Hunt-Hess scale
Grade 1 10; 24.4%
Grade 2 11 26.8%
Grade 3 20; 48.8%
Fisher scale
Grade 1 2; 4.9%
Grade 2 3; 7.3%
Grade 3 21; 51.2%
Grade 4 15; 36.6%
Abbreviations: ACA – anterior cerebral artery; MCA – middle cerebral
artery; ICA – internal carotid artery; ACoA – anterior communicat-
ing artery; WFNS – World Neurosurgical Federation Scale; GCS –
Glasgow Coma Scale.
Fig. 2 – Division of all complete fluid records into two
groups: 'DCI fluid measurements' and 'non-DCI fluid
measurements'. DCI – delayed cerebral ischaemia. Fluid
volume analyses were based on 322 complete records. The
number of 273 'non-DCI fluid measurements' contained
records of all patients who did not experience DCI as well
as from all patients before DCI incident. 'DCI fluid
measurements' consisted of 49 records after DCI diagnosis
when additional fluid intake was dispensed.
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later. Negative correlations between ﬂuid balance values and
time was also observed in non-DCI group (r = 0.25; p < 0.01).
The diagnosis of DCI caused a trend change; ﬂuid balance
scores were similar on consecutive days (r = 0.08; p = 0.58)
(Figs. 4 and 5).
4. Discussion
We focused on an issue omitted in literature: the adherence of
medical personnel to the departmental recommendations
which are based on low level evidence.Fig. 3 – The percentage of patients with complete fluid balance 
patients with CVL (lighter line). CVL – central venous line.4.1. Fluid balance charts
It is a commonly-held opinion that ﬂuid balance maintenance
of the unconscious patients in the NICU is veriﬁed more
scrupulously, in contrast to the conscious patients with oral
ﬂuid intake. Therefore, the conscious patients with oral ﬂuid
input are potentially at risk of iatrogenic ﬂuid imbalance.
However, as of yet the literature has not addressed whether
the same holds true for NICU patients after SAH. One of the
aims of our study was to examine this issue. The signiﬁcant
differences in ﬂuid chart completeness at our NICU and NHDU
suggest that more scrupulous bedside charting occurs in the
NICU than in NHDU. The same nurses rotate between the two
wards on a monthly basis and the typical ratio is 2 nurses peron the consecutive days (darker line). The percentage of
Fig. 4 – Fluid status, grouped according to DCI. DCI – delayed cerebral ischaemia.
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NICU and NHDU nursing staff in terms of years of education or
the length of experience with neurosurgical patient care. Since
the calculations of ﬂuid balance calculation takes place several
times a day on our ward, the miscalculations are not likely due
to a speciﬁc time during the shift [21].
Whiteley et al. ﬁrst mentioned the difﬁculty of maintaining
reliable ﬂuid charts of patients with SAH: only 1/3 of ﬂuid
charts were complete in her series. In our study, 1/4 of ﬂuid
charts were miscalculated. We made a step forward by
investigating the reasons for charts incompleteness. TheFig. 5 – Changes of positive fluid balpositive correlation between the presence of a CVL and the
ﬂuid balance completeness is difﬁcult to interpret and could be
incidental.
In our study, 1/4 of ﬂuid charts were miscalculated. Most of
the errors were attributable to omitted intravenous drugs
volume in the ﬂuid intake calculations. Data inaccuracy makes
proper sequential and incremental care virtually impossible,
challenges the outcome data as well as the validity of
documentation of ﬂuid management and underlines the need
for on-going and independent surveillance. Electronic bedside
charts can potentially reduce these errors [22]. It has beenance ratio on consecutive days.
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include clear departmental guidelines, signatures on the
nursing documentation and hypervolemic therapy revisions
in other NICU/NHDU departments [4]. Problems with doc-
umenting the ﬂuid balance are relevant not only to NICU but
also to other ICUs [23] and our study emphasised a signiﬁcant
difference in ﬂuid chart completion between the NICU and the
NHDU. However the positive correlation between the presence
of a CVL and the ﬂuid balance completeness is difﬁcult to
interpret and could be incidental.
The observation that mean and median ﬂuid intake
exceeded 3.5 and 3.8 l before and after DCI occurrence
respectively, may obscure another observation that less
than 3.3 l of ﬂuids were dispensed to as many as 1/4 of the
patients. Moreover, a positive ﬂuid balance was found only
in approximately 40% of measurements. The presence of
DCI did not signiﬁcantly increase the positive to negative
ﬂuid balance ratio. We hypothesise that the entire clinical
team was aware of the low level of evidence supporting the
new departmental ﬂuid recommendations. Therefore, our
results show the neurointensivists' reluctance to prescribe
large volumes of ﬂuids and the nurses' difﬁculties in
precisely measuring and calculating the resulting ﬂuid
balances. Speciﬁc reasons for inaccurate recording of
ﬂuid balance may be the ambulating patients' lack of
cooperation with nurses, imprecise (‘‘eyeball’’) measure-
ments, and insufﬁcient coordination of the measuring/
calculating process.
The inconsistent adherence to departmental recommen-
dations by both physicians and nurses revealed how
unconvincing the class IIa recommendations are. The
administration of additional ﬂuids after negative ﬂuid
balance occurrence was abandoned in approximately 40%
of our cases, regardless of DCI, which conﬁrms the above-
mentioned issue. Decisions on which of the ﬂuid therapy
approaches is the most appropriate for a speciﬁc case are not
always informed and makes is an task. This can then
compound a 'shared' responsibility of physicians and nurses.
Others also reported that adherence to evidence-based
management is suboptimal [24]. Whereas another study
shows that ofﬁcial multicentre programmes by a reputable
clinical research association can improve guideline adher-
ence [25].
4.2. Triple-H therapy
Our analysis only covered one component of triple-H therapy
and prophylaxis: hypervolemia. This may be considered as a
confounding factor of presented results. It is acknowledged
that patients after SAH are often hypovolemic due to
hypothalamic dysfunction and/or increased natriuretic pep-
tides secretion [26]. Although the validity of hypervolemic
therapy for CV prevention and treatment was discussed with
staff before initiating our study and after the results were
obtained, this did not inﬂuence the adherence to the
departmental guidelines.
Avoiding hypovolemia is advisable, but according to class
IIa, level B recommendations, there is no evidence that
hypervolemia is of any clinical utility prior to CV occurrence
[27]. Two randomised trials regarding hypervolemic CVprevention showed that triple-H therapy does not decrease
the CV incidence and does not inﬂuence neither early nor late
outcome [14,15]. Furthermore, the 2009 guidelines for ﬂuid
management after CV occurrence also provide class IIa, level B
recommendation [6]. Surprisingly, those recommendations
were based on the same 2 trials that questioned the usefulness
of triple-H therapy in CV prevention [14,15]. Thus in our study,
the hypervolemia for either CV prevention or treatment was a
weak treatment recommendation for the neurointensivists
and nurses [28,29].
The type of intravenous drugs and their volumes needed to
achieve the goal of hypervolemic therapy still remain
undeﬁned [8]. Compared with the clinical outcome, the impact
of hypervolemic hemodilution on physiological changes has
received more direct attention. Increased ﬂuid intake effec-
tively increases cardiac ﬁlling, but does not change net ﬂuid
balance, blood volume or cerebral blood ﬂow [15]. In contrast,
hypervolemia above 4 l increases blood pressure, blood
volume, cardiac output and cerebral blood ﬂow in patients
with CV [30]. A recent study examined the impact of extremely
increased ﬂuid intake (above 8 l per day) on ﬂuid balance, but
no signiﬁcant inﬂuence was detected [31]. If cerebral auto-
regulation is affected, cerebral blood perfusion depends on
cerebral blood ﬂow, thus the seeming inﬂuence of induced
hypervolemia on cerebral blood ﬂow is the most plausible.
However, a systematic review showed that the role of
hypervolemic therapy in cerebral blood ﬂow regulation after
SAH is at least weak [9].
4.3. Limitations
Our analysis only covered one component of triple-H therapy:
hypervolemia. Other potential sources of bias could be the
exclusion of SAH in poor condition and the fact that each
patient spent a different length of time at the NICU and NHDU.
4.4. Study outcome
The results of our audit were introduced to the NICU and
NHDU nursing staff and lead to procedural changes such as
the physicians' veriﬁcation of handwritten calculations and
reporting of every negative ﬂuid balance occurrence to a
neurointensivist. However errors may continue to happen
even after implementing a computerised calculation sys-
tem, so it is wise to always anticipate an error rate [32]. Use
of portable electronic devices for charting is considered by
our Department. However, the lack of consensus on ﬂuid
management after SAH persists among our medical staff.
5. Conclusions
Our study revealed numerous prescribing, measuring and
monitoring errors in the ﬂuid therapy of post-SAH patients.
Overall, the adherence to departmental recommendations
was suboptimal and we hypothesise this was due to the low
level of evidence supporting these recommendations. The
role of nurses in the effectiveness of the hypervolemic
component of the triple-H therapy should not be under-
estimated.
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